Product Description
Arbaclofen placarbil is a novel transported prodrug of the pharmacologically active R-isomer of baclofen designed to be absorbed throughout the intestine by both passive and active mechanisms via the monocarboxylate type 1 transporter. Arbaclofen placarbil is rapidly converted to R-baclofen in human and animal tissues in vitro.
Mechanisms of Action: GABA Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: XenoPort
Company Location: REDWOOD CITY CA 94063
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Multiple Sclerosis
Phase 2: Gastroesophageal Reflux|Bile Reflux|Back Pain|Esophagitis, Peptic|Alcoholism|Muscle Spasticity|Spinal Cord Injuries
Phase 1: Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| INDV-AP-102 | P1 |
Completed |
Healthy Volunteers |
2017-07-05 |
|
| RB-US-14-0001 | P2 |
Completed |
Alcoholism |
2016-01-01 |
|
| XP-B-089 | P3 |
Completed |
Multiple Sclerosis |
2013-02-01 |
81% |
| XP-B-078 | P2 |
Completed |
Gastroesophageal Reflux|Esophagitis, Peptic |
2010-12-01 |
25% |